News - November 24, 2020
Join us: RARE Conversations Breakfast Briefing
RARE Conversations Breakfast Briefing
Impact of COVID-19 on Pharmaceutical Research and Development
in Rare Diseases
3 December 2020 | 10.00 – 11.15 CET
Europe has long been at the forefront in healthcare and is home to many leading healthcare professionals, academia and the innovative pharmaceutical industry that together have fought relentlessly to improve patients’ lives. However, the COVID-19 pandemic has made evident, that Europe’s regulatory framework must keep the pace with innovation, if we want to continue to bring treatments to patients of high quality, safety, and efficacy. To meet the challenges of tomorrow, we need increased global cooperation, regulatory convergence, and a striking balance between regulatory flexibility and predictability.
EUCOPE and its member Alexion are delighted to share the experience with you on the impact that COVID-19 had on patients’ life as well as on research and development in Europe. By sharing this experience, we aim at developing a shared vision on how to respond to the opportunities and challenges of tomorrow and working towards a Europe that puts research and development in healthcare first, to deliver better treatment and care to patients.
10.00 Welcome statement by Maciej Gajewski, Executive Director and Head of International Government Affairs and Policy, Alexion
10.05 Open poll with audience
10.10 Introductory remarks by Dr Alexander Natz, Secretary General, EUCOPE
10.20 Panel discussion with
- Dr Martine Zimmermann, Senior Vice President Global Regulatory Affairs, Alexion
- Dimitrios Athanasiou, Board member, European Patients’ Forum (EPF) and EMA Paediatric Committee (PDCO) Member
- Dr Thomas Lönngren, Strategic Advisor, NDA Group and former Executive Director of the European Medicines Agency